Major Pathologic Response after Induction Therapy Has a Long-Term Impact on Survival and Tumor Recurrence in Stage IIIA/B Locally Advanced NSCLC
01 October 2018
14 January 2019
26 February 2019 (online)
Background Major pathologic response (MPR) determines favorable outcome in locally advanced non-small cell lung cancer after induction therapy (IT) followed by lung resection. The aim of this retrospective study was to identify the prognostic relevance of MPR in long-term interval.
Methods In 55 patients, the survival rate according to MPR and non-MPR was estimated by Kaplan–Meier method and compared using log-rank, Breslow, and Tarone–Ware tests.
Results The IT included chemoradiation with 50.4 Gy (range: 45–56.4 Gy) combined with platinum-based chemotherapy in 52 patients (94.5%) and platinum-based chemotherapy in 3 patients (5.5%). Perioperative morbidity and 30-day mortality were 36 and 3.6%, respectively. The estimated 5-year postoperative and progressive-free survivals were statistically significantly improved in MPR versus non-MPR with 53.5 versus 18% and 49.4 versus 18.5%, respectively. According to the log-rank, Breslow, and Tarone–Ware tests, the MPR demonstrates prognostic significance in early, long-term, and whole postoperative interval.
Conclusion MPR is associated with a robust correlation to long-term postoperative and recurrence-free survival improvement, and can potentially simplify the multidisciplinary debate and allow further stratification of adjuvant treatment in multimodality therapy.
- 1 De Ruysscher D, Vansteenkiste J, Belderbos J, Decaluwé H, Dingemans AM. The optimal local treatment of stage IIIA-N2 NSCLC: is the issue finally settled?. J Thorac Oncol 2016; 11 (03) 284-286
- 2 van Meerbeeck JP. The controversial role of surgery in stage III NSCLC. Lancet Oncol 2008; 9 (07) 607-608
- 3 Mirimanoff RO. Neoadjuvant chemoradiotherapy followed by surgery for stage IIIa and IIIb non-small-cell lung cancer (NSCLC): is it still justified?. Linchuang Zhongliuxue Zazhi 2015; 4 (04) 49-57
- 4 Lococo F, Cesario A, Margaritora S. , et al. Long-term results in patients with pathological complete response after induction radiochemotherapy followed by surgery for locally advanced non-small-cell lung cancer. Eur J Cardiothorac Surg 2013; 43 (03) e71-e81
- 5 Pataer A, Kalhor N, Correa AM. , et al; University of Texas M. D. Anderson Lung Cancer Collaborative Research Group. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. J Thorac Oncol 2012; 7 (05) 825-832
- 6 Hellmann MD, Chaft JE, William Jr WN. , et al; University of Texas MD Anderson Lung Cancer Collaborative Group. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol 2014; 15 (01) e42-e50
- 7 Cascone T, Gold KA, Swisher SG. , et al. Induction cisplatin docetaxel followed by surgery and erlotinib in non-small cell lung cancer. Ann Thorac Surg 2018; 105 (02) 418-424
- 8 Eisenhauer EA, Therasse P, Bogaerts J. , et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45 (02) 228-247
- 9 Junker K, Thomas M, Schulmann K, Klinke F, Bosse U, Müller KM. Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment. J Cancer Res Clin Oncol 1997; 123 (09) 469-477
- 10 Junker K. Tumour regression in non-small-cell lung cancer following neoadjuvant therapy, a significant prognostic factor. J Cancer Res Clin Oncol 1998; 124: 283-284
- 11 Goldstraw P, Chansky K, Crowley J. , et al; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee Advisory Boards and Participating Institutions. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2016; 11 (01) 39-51
- 12 Blumenthal GM, Bunn Jr PA, Chaft JE. , et al. Current status and future perspectives on neo-adjuvant therapy in lung cancer. J Thorac Oncol 2018; 13 (12) 1818-1831
- 13 Crabtree TD, Sharma A. Is there any role for positron emission tomography-computed tomography after induction therapy for locally advanced non-small cell lung cancer?. J Thorac Cardiovasc Surg 2016; 151 (04) 911-912
- 14 Kappers I, van Sandick JW, Burgers JA. , et al. Results of combined modality treatment in patients with non-small-cell lung cancer of the superior sulcus and the rationale for surgical resection. Eur J Cardiothorac Surg 2009; 36 (04) 741-746
- 15 Nason KS. Is there a role for postinduction positron emission tomography and computed tomography with fludeoxyglucose F 18? A call for standardization. J Thorac Cardiovasc Surg 2016; 151 (04) 980-981
- 16 Schreiner W, Gavrychenkova S, Dudek W. , et al. Pathologic complete response after induction therapy-the role of surgery in stage IIIA/B locally advanced non-small cell lung cancer. J Thorac Dis 2018; 10 (05) 2795-2803
- 17 Pöttgen C, Stuschke M, Graupner B. , et al. Prognostic model for long-term survival of locally advanced non-small-cell lung cancer patients after neoadjuvant radiochemotherapy and resection integrating clinical and histopathologic factors. BMC Cancer 2015; 15: 363
- 18 Massard G, Kessler R, Wihlm JM. Improved selection of winners: a working hypothesis for neoadjuvant chemotherapy. Ann Thorac Surg 1998; 66 (01) 300-301
- 19 Cerfolio RJ, Maniscalco L, Bryant AS. The treatment of patients with stage IIIA non-small cell lung cancer from N2 disease: who returns to the surgical arena and who survives. Ann Thorac Surg 2008; 86 (03) 912-920 , discussion 912–920
- 20 Isobe K, Hata Y, Sakaguchi S. , et al. Pathological response and prognosis of stage III non-small cell lung cancer patients treated with induction chemoradiation. Asia Pac J Clin Oncol 2012; 8 (03) 260-266
- 21 Schreiner W, Dudek W, Lettmaier S, Gavrychenkova S, Rieker R, Fietkau R, Sirbu H. Neoadjuvant radiochemotherapy followed by curative resection in patients with advanced non-small cell lung cancer in stage IIIA/IIIB: prognostic factors and results. Zentralbl Chir 2016; 141: 323-329